Medical technology company Intelligent Bio Solutions Inc. (Nasdaq: INBS) is pioneering fast, intelligent, and non-invasive testing solutions. The company's flagship product, the Intelligent Fingerprinting Drug Screening System, offers a rapid alternative to traditional urine testing methods, ensuring employees are "Fit to Work." As stated by Doug Heath, Vice President of Global Sales at INBS, in their news release on July 9, 2024.

Workplace impairment due to drugs and alcohol significantly increases the risk of worker injuries. According to the Health and Safety Executive (HSE), the UK manufacturing sector reported a significant rate of non-fatal workplace injuries, with 1,740 injuries per 100,000 workers in 2022/23. These statistics highlight the urgent need for effective drug screening methods to ensure worker safety.

The Intelligent Fingerprinting Drug Screening System from Intelligent Bio Solutions addresses this necessity by providing accurate and reliable drug testing. The system can screen for common drugs such as methamphetamine, opiates, cocaine, and cannabis through the analysis of sweat from an individual’s fingerprints. This method offers a much more convenient and faster alternative to traditional urine testing methods. Companies using the system have reported not only quick results but also enhanced operational efficiency.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is rapidly expanding its footprint across the UK, New Zealand, Australia, and various parts of Europe, targeting multiple sectors with its innovative testing solutions. The company has ambitious plans to enter the US market in 2025, signaling a significant growth opportunity.

Although the stock is currently underperforming, a market reversal may be on the horizon. INBS reached a closing high of $6.70 per share and an intraday high of $11.70 in 2024, indicating its potential for substantial upside. Investors should consider the company's accelerating expansion and the anticipated entry into the lucrative US market as key factors for future growth.

Healthcare Stocks with Market Turnaround Potential Start Upticking: Zevra Therapeutics (NASDAQ: ZVRA), Relmada Therapeutics (NASDAQ: RLMD), ZyVersa Therapeutics (NASDAQ: ZVSA), Entero Therapeutics (NASDAQ: ENTO).

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com